What makes tesamorelin the most clinically validated GHRH peptide?

Tesamorelin is the only GHRH analogue approved by the FDA (as Egrifta) and has completed multiple Phase 3 clinical trials with thousands of patients. This level of clinical validation is unique among research GHRH peptides. The trials specifically documented visceral fat reduction, lipid profile improvements, and the safety and tolerability profile.

Does tesamorelin work for visceral fat reduction outside HIV lipodystrophy?

The FDA approval is specifically for HIV-associated lipodystrophy. However, research has expanded to other contexts including age-related GH decline, abdominal obesity, and most recently cognitive function in MCI. The mechanism (GH-driven visceral lipolysis) is not specific to HIV - it operates through universal GH signalling pathways.

How does tesamorelin compare to CJC-1295 for GH stimulation?

Tesamorelin is full-length GHRH(1-44) with an N-terminal modification, while CJC-1295 is a modified fragment (1-29). Both bind GHRH receptors with high affinity. Tesamorelin has more clinical data. CJC-1295 with DAC has a much longer half-life (days vs minutes). For studies requiring pulsatile patterns with full-length GHRH, tesamorelin is preferred.

Trending

Tesamorelin

Name: Tesamorelin
Price: 70 USD
Availability: InStock

FDA-approved GHRH analogue (Egrifta) for HIV-associated visceral fat reduction. The most clinically validated GHRH peptide for abdominal fat mobilisation and

GH BoostFat Loss

● In Stock

Select Variant

Quantity (vials)

Buy more, save more

—

1+ vials

−5%

3+ vials

−10%

5+ vials

−20%

10+ vials

Total Price

$70

For research & laboratory use only. Not for human consumption.

Half-Life

~26-38 minutes

Administration Route

Subcutaneous injection

Visceral Fat Reduction

Only peptide FDA-approved specifically for abdominal fat

HIV Lipodystrophy

Approved for antiretroviral-induced lipodystrophy

Cardiovascular Benefit

Reduces triglycerides and carotid IMT alongside fat loss

Effect Profile

Based on primary research mechanisms

Muscle Growth

Fat Oxidation

Recovery Speed

Strength

Effect Timeline

Start

Visceral fat reduction begins; GH levels elevated

Week 8

Measurable abdominal fat loss; IGF-1 normalised

Week 16

15–20% visceral fat reduction; triglycerides declining

Week 24

Maximum fat loss achieved; cardiovascular risk markers improved

Start — Week 4